Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece

被引：0
|
作者：
Tzanetakos, C. [1 ]
Kourlaba, G. [2 ]
Hatzikou, M. [3 ]
Antoniou, C. [4 ]
Ioannides, D. [5 ]
Lefaki, I. [6 ]
Petridis, A. [7 ]
Rigopoulos, D. [8 ]
Roussaki-Schulze, V. [9 ]
Sotiriadis, D. [10 ]
Maniadakis, N. [1 ]
机构：
[1] Natl Sch Publ Hlth, Hlth Serv Org & Management, Athens, Greece
[2] Aghia Sophia Childrens Hosp, Collaborat Ctr Clin Epidemiol & Outcomes Res CLEO, Athens, Greece
[3] Novartis Hellas SACI SA, Athens, Greece
[4] Univ Athens, Hosp Venereol Dermatol Dis A Syggros, Athens, Greece
[5] Aristoteleio Univ Thessaloniki, Hosp Skin & Venereal Dis, Thessaloniki, Greece
[6] Hosp Skin & Venereal Dis, Dermatol Clin, Thessaloniki, Greece
[7] Hosp Venereol Dermatol Dis A Syggros, Dermatol Clin, Athens, Greece
[8] Univ Athens, Attikon Univ Hosp Athens, Athens, Greece
[9] Univ Thessaly, Univ Hosp Larissa, Larisa, Greece
[10] Aristoteleio Univ Thessaloniki, Gen Hosp Thessaloniki PAPAGEORGIOU, Thessaloniki, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
cost-effectiveness; plaque psoriasis; secukinumab;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P125
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF APREMILAST IN MODERATE-TO-SEVERE PSORIASIS IN CANADA
    Cawston, H.
    Damera, V
    Ektare, V
    Shear, N. H.
    Tencer, T.
    Liu, F. F.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
  • [42] Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK
    Mughal, F.
    Barker, J.
    Cawston, H.
    Damera, V.
    Bewley, A.
    Morris, J.
    Shaw, T.
    Tencer, T.
    Zhang, F.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 74 - 74
  • [43] COST PER RESPONDER OF USTEKINUMAB VERSUS ETANERCEPT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS FROM THE ACCEPT TRIAL
    Feldman, S. R.
    Augustin, M.
    Martin, S.
    Szapary, P.
    Schenkel, B.
    VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
  • [44] A COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB 300 MG VS CURRENT THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN ITALY
    D'Ausilio, A.
    Aiello, A.
    Daniel, F.
    Graham, C.
    Roccia, A.
    Toumi, M.
    VALUE IN HEALTH, 2015, 18 (07) : A424 - A424
  • [45] COST EFFICACY OF USTEKINUMAB IN TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN TURKEY
    Tatar, M.
    Sarioz, F.
    VALUE IN HEALTH, 2010, 13 (03) : A146 - A147
  • [46] Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis
    Wong, Ian T. Y.
    Shojania, Kam
    Dutz, Jan
    Tsao, Nicole W.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 153 - 166
  • [47] Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 173 - 178
  • [48] Cost-effectiveness analysis of amevivetm (Alefacept) in the treatment of patients with moderate-to-severe psoriasis
    Iskedjian, M
    Barkovsky, L
    Desjardins, O
    Walker, JH
    Dorkalam, M
    Shear, N
    Einarson, TR
    VALUE IN HEALTH, 2005, 8 (03) : 330 - 330
  • [49] Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment
    Wu, Jashin J.
    Rastogi, Shipra
    Menges, Brandy
    Lingohr-Smith, Melissa
    Lin, Jay
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB83 - AB83
  • [50] Cost effectiveness - Analysis of Therapy with Ustekinumab versus Etanercept in Patients with moderate to severe Plaque Psoriasis Based on the ACCEPT Study
    Augustin, M.
    Feldman, S.
    Wolbring, F.
    Szapary, P.
    Schenkel, B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 : 191 - 191
12345